Botulinum toxin A for bladder pain syndrome/interstitial cystitis
Journal
Toxins
Journal Volume
8
Journal Issue
7
Date Issued
2016
Author(s)
Abstract
Botulinum neurotoxin A (BoNT-A), derived from Clostridium botulinum, has been used clinically for several diseases or syndrome including chronic migraine, spasticity, focal dystonia and other neuropathic pain. Chronic pelvic or bladder pain is the one of the core symptoms of bladder pain syndrome/interstitial cystitis (BPS/IC). However, in the field of urology, chronic bladder or pelvic pain is often difficult to eradicate by oral medications or bladder instillation therapy. We are looking for new treatment modality to improve bladder pain or associated urinary symptoms such as frequency and urgency for patients with BPS/IC. Recent studies investigating the mechanism of the antinociceptive effects of BoNT A suggest that it can inhibit the release of peripheral neurotransmitters and inflammatory mediators from sensory nerves. In this review, we will examine the evidence supporting the use of BoNTs in bladder pain from basic science models and review the clinical studies on therapeutic applications of BoNT for BPS/IC. ? 2016 by the authors; licensee MDPI, Basel, Switzerland.
Subjects
Botulinum toxin A; Cystitis; Interstitial cystitis; Intravesical injection
SDGs
Other Subjects
botulinum toxin A; calcitonin gene related peptide; capsaicin; neurotransmitter; purinergic P2X receptor; transient receptor potential channel A1; acetylcholine release inhibitor; botulinum toxin A; bladder biopsy; bladder irrigation; cystalgia; disease assessment; endocytosis; focal dystonia; human; inflammation; inflammatory mediator; interstitial cystitis; interstitial cystitis symptom index; neuropathic pain; nocturia; nonhuman; pelvis pain syndrome; prostatitis; Review; spasticity; transformed migraine; visual analog scale; animal; bladder; chronic pain; innervation; interstitial cystitis; intravesical drug administration; pathophysiology; pelvic pain; treatment outcome; Acetylcholine Release Inhibitors; Administration, Intravesical; Animals; Botulinum Toxins, Type A; Chronic Pain; Cystitis, Interstitial; Humans; Pelvic Pain; Treatment Outcome; Urinary Bladder
Type
journal article